Fluorouracil

證據等級: L5

預測適應症: 10 個

Fluorouracil: From Systemic Antineoplastic Therapy to Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina

One-Sentence Summary

Fluorouracil (5-FU) is a long-established fluoropyrimidine antimetabolite used systemically across multiple solid tumours, but this evidence pack does not contain New Zealand-specific original indication data because the product is not currently marketed in New Zealand. The TxGNN model's top-ranked prediction for this drug is Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina, an ultra-rare paediatric sarcoma subtype, with a very high similarity score (99.75%) — however, this prediction is currently supported by zero clinical trials and zero publications, meaning it is a pure computational (knowledge-graph embedding) association with no direct evidentiary backing.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack — product is not marketed in New Zealand, so no approved indication text is on file
Predicted New Indication	Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina
TxGNN Prediction Score	99.75%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack (flagged as a High-severity data gap requiring DrugBank lookup). Based on well-established general pharmacological knowledge, fluorouracil (5-FU) is a pyrimidine analogue that, after metabolic activation, inhibits thymidylate synthase, blocking DNA synthesis and exerting non-specific cytotoxicity against rapidly dividing cells — this is the basis of its long-standing use across a broad range of systemic chemotherapy regimens for solid tumours.

The proposed link to botryoid-type embryonal rhabdomyosarcoma of the vagina rests solely on this general "highly proliferative tumour → antimetabolite cytotoxicity" logic. Embryonal rhabdomyosarcoma cells do divide rapidly, so a theoretical rationale for antiproliferative activity exists. However, the standard-of-care regimen for this subtype (VAC/VAI: vincristine, actinomycin D, cyclophosphamide or ifosfamide) does not include 5-FU, and there is no clinical trial or published case series testing 5-FU in this indication. The mechanistic link is therefore inferential only, not corroborated by any disease-specific data — consistent with the TxGNN model surfacing a knowledge-graph similarity rather than a validated pharmacological signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

New Zealand Market Information

Fluorouracil is not currently marketed in New Zealand — Medsafe records show 0 product authorizations, so no licensed product/indication information is available.

Cytotoxicity

Fluorouracil is a conventional cytotoxic antineoplastic agent (fluoropyrimidine antimetabolite class), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (fluoropyrimidine antimetabolite)
Myelosuppression Risk	Moderate–High (class effect of fluoropyrimidines, typically neutropenia and thrombocytopenia) — please refer to the package insert warnings and precautions for product-specific data
Emetogenicity Classification	Low to Moderate (typical for fluoropyrimidine-based regimens)
Monitoring Items	Complete blood count with differential, liver and renal function, electrolytes; cardiac monitoring given known fluoropyrimidine cardiotoxicity risk; DPD deficiency status where feasible
Handling Protection	Yes — must be handled under standard cytotoxic/hazardous drug handling precautions

Note: No product-specific toxicity data was found in DrugBank or TFDA/Medsafe sources for this evidence pack; the above reflects established fluoropyrimidine class knowledge. Please refer to the package insert warnings and precautions for definitive guidance.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN similarity score is high, but this indication (botryoid-type embryonal rhabdomyosarcoma of the vagina) has no clinical trials and no published literature supporting 5-FU use, and it falls outside current standard-of-care regimens for this tumour subtype. This is an L5, model-prediction-only signal and does not meet the threshold to advance beyond initial screening.

To proceed, the following is needed:

TFDA/Medsafe package insert data (warnings, contraindications) — currently a Blocking data gap preventing safety (S1) evaluation
Confirmed mechanism-of-action data from DrugBank — currently a High-severity data gap
Any preclinical or mechanistic studies specific to embryonal rhabdomyosarcoma (none currently identified)
Consideration of re-prioritizing evaluation toward other candidates in this same evidence pack with materially stronger evidence — notably liver sarcoma (rank 7, evidence level L3, 6 clinical trials incl. one directly using fluorouracil-containing FOLFIRINOX, 20 publications, decision stage "Research Question"), which currently represents the most evidence-rich repurposing signal for this drug
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.